SGLT2i vs. DPP4i Comparison in T2D Patients with PAD

Among patients with T2D who had undergone PAD revascularization, 2,455 and 8,695 had received first prescriptions for SGLT2i and DPP4i, respectively, between May 1, 2016, and December 31, 2019. The SGLT2i agents were dapagliflozin, empagliflozin, and canagliflozin and were prescribed to 997 (40.61%), 1305 (53.16%), and 153 (6.23%) patients, respectively. The DPP4i agents were sitagliptin, vildagliptin, linagliptin, saxagliptin, and alogliptin and were prescribed to 1,875 (21.56%), 1,780 (20.47%), 4,436 (51.02%), 562 (6.46%), and 42 (0.48%) patients, respectively. Before PSM, we observed that compared with the DPP4i group, the SGLT2i group was younger; had a male predominance; had a lower prevalence of chronic kidney disease (CKD), hypertension, and malignancy; had a higher prevalence of dyslipidemia, ischemic heart disease, and history of percutaneous coronary intervention; and had a higher rate of prescriptions for metformin, sulfonylurea, acarbose, glitazones, antiplatelet agents, angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEIs/ARBs), beta blockers, statins, direct oral anticoagulants, mineralocorticoid receptor antagonists, and angiotensin receptor–neprilysin inhibitors (ASMD > 0.1). After PSM, the two study groups were well balanced in all baseline characteristics (ASMD < 0.1; Table 1).